Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1. Treat CEA positive rectal cancer via Trained Immunity. 2. Activate human CEA Protein Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the CEA protein antigen into small peptide fragments, and then kill CEA positive rectal cancer cells in vivo.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
20 Rectal Cancer Participants with CEA blood test
Timeframe: Duration up to 90 days
20 Rectal Cancer Participants with IGRA blood test with CEA protein antigen
Timeframe: Duration up to 90 days
20 Rectal Cancer Participants with IGRA blood test with TB antigens
Timeframe: Duration up to 90 days